Skip to main content

Main menu

Home
Content
Subscriptions
Authors
Info
About
More
- Alerts
- Feedback
- Help
- SNMMI Journals

SNMMI
- JNM
- JNMT
- SNMMI Journals
- SNMMI

User menu

Subscribe
My alerts
Log in
Log out
My Cart

Search

Search for this keyword

Advanced search

SNMMI
- JNM
- JNMT
- SNMMI Journals
- SNMMI

Subscribe
My alerts
Log in
Log out
My Cart

Search for this keyword

Advanced Search

Home
Content
Subscriptions
Authors
Info
About
More
- Alerts
- Feedback
- Help
- SNMMI Journals

View or Listen to JNM Podcast
Visit JNM on Facebook
Join JNM on LinkedIn
Follow JNM on Twitter
Subscribe to our RSS feeds

Research ArticleTheranostics

Open Access

Imaging DNA Damage Repair In Vivo After ¹⁷⁷Lu-DOTATATE Therapy

Edward O’Neill, Veerle Kersemans, P. Danny Allen, Samantha Y.A. Terry, Julia Baguña Torres, Michael Mosley, Sean Smart, Boon Quan Lee, Nadia Falzone, Katherine A. Vallis, Mark W. Konijnenberg, Marion de Jong, Julie Nonnekens and Bart Cornelissen

Journal of Nuclear Medicine May 2020, 61 (5) 743-750; DOI: https://doi.org/10.2967/jnumed.119.232934

Edward O’Neill

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Veerle Kersemans

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

P. Danny Allen

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Samantha Y.A. Terry

2Department of Imaging Chemistry and Biology, King’s College London, London, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Julia Baguña Torres

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Mosley

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sean Smart

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Boon Quan Lee

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nadia Falzone

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Katherine A. Vallis

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark W. Konijnenberg

3Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marion de Jong

3Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Julie Nonnekens

3Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

4Department of Molecular Genetics, Erasmus MC, Rotterdam, The Netherlands; and

5Oncode Institute, Erasmus MC, Rotterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bart Cornelissen

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

In this issue

Journal of Nuclear Medicine: 61 (5)

Journal of Nuclear Medicine

Vol. 61, Issue 5

May 1, 2020

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Print

User Name *

Password *

Sign In to Email Alerts with your Email Address

Email *

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Imaging DNA Damage Repair In Vivo After ¹⁷⁷Lu-DOTATATE Therapy

Edward O’Neill, Veerle Kersemans, P. Danny Allen, Samantha Y.A. Terry, Julia Baguña Torres, Michael Mosley, Sean Smart, Boon Quan Lee, Nadia Falzone, Katherine A. Vallis, Mark W. Konijnenberg, Marion de Jong, Julie Nonnekens, Bart Cornelissen

Journal of Nuclear Medicine May 2020, 61 (5) 743-750; DOI: 10.2967/jnumed.119.232934

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Share

Imaging DNA Damage Repair In Vivo After ¹⁷⁷Lu-DOTATATE Therapy

Edward O’Neill, Veerle Kersemans, P. Danny Allen, Samantha Y.A. Terry, Julia Baguña Torres, Michael Mosley, Sean Smart, Boon Quan Lee, Nadia Falzone, Katherine A. Vallis, Mark W. Konijnenberg, Marion de Jong, Julie Nonnekens, Bart Cornelissen

Journal of Nuclear Medicine May 2020, 61 (5) 743-750; DOI: 10.2967/jnumed.119.232934

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Related Articles

This Month in JNM

PubMed
Google Scholar

Cited By...

Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy

Google Scholar

More in this TOC Section

Theranostics

Can ¹⁷⁷Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
Determination of the Intralesional Distribution of Theranostic ¹²⁴I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data

Show more Theranostics

Basic

Dopamine D₁ Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
Synthesis and Preclinical Evaluation of a ⁶⁸Ga-Labeled Adnectin, ⁶⁸Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression

Show more Basic

Similar Articles

Keywords

177Lu-DOTATATE
γH2AX
SPECT
DNA damage
neuroendocrine cancer

© 2025 SNMMI